Mesoblast (ASX:MSB), a company focused on allogeneic cellular medicines for inflammatory diseases, announced that pricing information for its product, Ryoncil (remestemcel-L), is now included in all four major drug pricing compendia in the United States.
The listing follows the US Food and Drug Administration's approval and publication of a revised Ryoncil label, which includes updates to Section 16 (How Supplied / Storage and Handling) of the product prescribing information.
The revisions introduce eight new Ryoncil kits, each assigned a unique National Drug Code, allowing treatment centres to order kits tailored to patient-specific weight-based dosages.
The pricing structure ensures uniform pricing regardless of patient weight.
The four drug pricing compendia now listing Ryoncil include: Merative Micromedex RED BOOK, First Databank FDB MedKnowledge drug pricing, Elsevier Gold standard drug database and Wolters Kluwer Medi-Span price Rx.
These compendia serve as official sources for ordering information, including product manufacturing details, kit pricing, and NDCs.
At the time of reporting, Mesoblast's share price was $2.10.